Literature DB >> 22058053

Methods to assess neuroinflammation.

Florianne Monnet-Tschudi1, Antoinette Defaux, Olivier Braissant, Laurène Cagnon, Marie-Gabrielle Zurich.   

Abstract

Neuroinflammation is observed in many brain pathologies: in neurodegenerative diseases and multiple sclerosis as well as in chemically induced lesions. It is characterized by the reactivity of microglial cells and astrocytes, activation of inducible NO-synthase (i-NOS), and increased expression and/or release of cytokines and chemokines. Clearly, cell-to-cell signaling between the different brain cell types plays an important role in the initiation and propagation of neuroinflammation, but despite the growing list of known molecular actors, the underlying pathways and the sequence of events remain to be fully elucidated. The present chapter presents an example of how to assess neuroinflammation in complex brain tissues, using aggregating brain cell cultures as an in vitro model. This three-dimensional cell culture system provides optimal cell-to-cell interactions crucial for histotypic cellular maturation and control of neuroinflammatory processes. The techniques described here comprise immunocytochemistry to assess the reactivity of microglia and astrocytes and the expression of cytokines; quantitative RT-PCR to measure the mRNA expression of cytokines (TNF-α, IL-1β, IL-6, IL-1ra, TGF-β, IL-15, IFN-γ), chemokines (ccl5, cxcl1, cxcl2), and i-NOS; and immunoblotting to assess MAP kinase pathway activation (phosphorylation of p38 and p44/42 MAP kinases).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22058053     DOI: 10.1002/0471140856.tx1219s50

Source DB:  PubMed          Journal:  Curr Protoc Toxicol        ISSN: 1934-9254


  9 in total

Review 1.  Immune dysregulation in autism spectrum disorder.

Authors:  Daniela Briceno Noriega; Huub F J Savelkoul
Journal:  Eur J Pediatr       Date:  2013-12-03       Impact factor: 3.183

2.  Glia maturation factor induces interleukin-33 release from astrocytes: implications for neurodegenerative diseases.

Authors:  Duraisamy Kempuraj; Mohammad Moshahid Khan; Ramasamy Thangavel; Zhi Xiong; Evert Yang; Asgar Zaheer
Journal:  J Neuroimmune Pharmacol       Date:  2013-02-10       Impact factor: 4.147

Review 3.  Evidence of microglial activation in autism and its possible role in brain underconnectivity.

Authors:  Juan I Rodriguez; Janet K Kern
Journal:  Neuron Glia Biol       Date:  2012-07-06

4.  Tollip, an early regulator of the acute inflammatory response in the substantia nigra.

Authors:  Marie Humbert-Claude; D Duc; D Dwir; L Thieren; J Sandström von Tobel; C Begka; F Legueux; D Velin; M H Maillard; K Q Do; F Monnet-Tschudi; L Tenenbaum
Journal:  J Neuroinflammation       Date:  2016-12-07       Impact factor: 8.322

Review 5.  An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.

Authors:  Andrea Terron; Anna Bal-Price; Alicia Paini; Florianne Monnet-Tschudi; Susanne Hougaard Bennekou; Marcel Leist; Stefan Schildknecht
Journal:  Arch Toxicol       Date:  2017-12-05       Impact factor: 5.153

Review 6.  Role of Neuroinflammation in Autism Spectrum Disorder and the Emergence of Brain Histaminergic System. Lessons Also for BPSD?

Authors:  Nermin Eissa; Adel Sadeq; Astrid Sasse; Bassem Sadek
Journal:  Front Pharmacol       Date:  2020-06-16       Impact factor: 5.810

7.  Glial cell diversity and methamphetamine-induced neuroinflammation in human cerebral organoids.

Authors:  Jason Dang; Shashi Kant Tiwari; Kriti Agrawal; Hui Hui; Yue Qin; Tariq M Rana
Journal:  Mol Psychiatry       Date:  2020-02-12       Impact factor: 15.992

Review 8.  Relevance of Neuroinflammation and Encephalitis in Autism.

Authors:  Janet K Kern; David A Geier; Lisa K Sykes; Mark R Geier
Journal:  Front Cell Neurosci       Date:  2016-01-19       Impact factor: 5.505

9.  Cross-talk between microglia and neurons regulates HIV latency.

Authors:  David Alvarez-Carbonell; Fengchun Ye; Nirmala Ramanath; Yoelvis Garcia-Mesa; Pamela E Knapp; Kurt F Hauser; Jonathan Karn
Journal:  PLoS Pathog       Date:  2019-12-30       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.